Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Revumenib in Relapsed/Refractory Leukemias
NCT04065399Phase 2Recruiting
- Sponsor
- Syndax Pharmaceuticals
- Start
- Nov 2019
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 11
01
Overview
A Phase 2 trial of revumenib in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), mixed phenotype acute leukemia (MPAL), acute leukemia of ambiguous lineage (ALAL), sponsored by Syndax Pharmaceuticals. Started Nov 2019; status: recruiting.
02
Drugs
revumenib
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)mixed phenotype acute leukemia (MPAL)acute leukemia of ambiguous lineage (ALAL)
Beyond the preview
Go deeper on NCT04065399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04065399.